Still Eating on Mounjaro — What Your Appetite Is (and Isn't) Telling You

Step 1: The first pen, why hunger often barely budges

The opening dose of tirzepatide is 2.5 mg. Its job is to let your body adjust to the medicine, not to produce dramatic appetite suppression. Many people finish their first four weeks eating fairly normally and wonder whether anything is happening at all. That is the expected experience, not evidence of a problem.

The NHS medicines information for tirzepatide explains that treatment is titrated gradually by the prescriber, typically stepping up every four weeks. The 2.5 mg pen is the adjustment phase. Expecting transformative hunger control from it is like expecting a car to be at cruising speed while the engine is still warming up.

Some people do notice a reduction even at this stage, less interest in snacking, feeling full more quickly. Others notice almost nothing. Both are within normal range. If you are finding this early period frustrating, the guide on still feeling hungry on Mounjaro covers common reasons and what typically helps.

Step 2: Dose increases, when the effect usually deepens

The clearest reduction in appetite for most people arrives after moving up to 5 mg, and again at subsequent steps. This is the pattern seen across the SURMOUNT-1 clinical trial, in which participants continued to lose weight throughout 72 weeks, meaning appetite regulation and weight reduction were not front-loaded events but sustained processes tied to escalating doses.

So if you are still eating fairly normally at 2.5 mg or just after a step-up, the honest answer is: wait. Give the new dose four weeks. The body needs time to respond to the changed receptor signal. Changing habits mid-titration (drastically cutting calories, skipping meals) can actually make nausea worse without meaningfully accelerating results.

For a broader look at what food choices tend to sit well during treatment, our guide on what to eat on Mounjaro covers protein, fibre and meal timing in practical terms. The short version: small, protein-led meals eaten slowly tend to work better than large portions eaten quickly, simply because gastric emptying is slower on tirzepatide.

Step 3: Eating is not the obstacle, how you eat matters more than whether you eat

A common concern is that still eating means the medicine is not working. It almost never does. Weight loss on tirzepatide in clinical trials came from a modest, sustained calorie reduction over many months, not from people stopping eating. The SURMOUNT-1 data (published in the New England Journal of Medicine) showed an average body-weight reduction of around 20–21% at the 15 mg dose across 72 weeks, that is not achieved by not eating; it is achieved by consistently eating a little less, while the medicine does the heavy lifting on hunger signals.

Protein adequacy matters. When overall food intake drops, the risk is that muscle mass decreases alongside fat. Prioritising protein at each meal (eggs, fish, chicken, legumes, Greek yoghurt) helps preserve muscle. Hydration matters too: dehydration is easy to miss when appetite is lower and you are reaching for fewer drinks alongside meals. If you want to understand the detail of eating on Mounjaro more broadly, that page covers both the physiology and the practical meal approach.

One thing our prescribers hear fairly regularly: people who feel anxious about still wanting food after a dose increase, and who start skipping meals deliberately. That tends to backfire. Extreme under-eating can cause fatigue, poor concentration and muscle loss, and it makes the gastrointestinal side effects that some people experience feel considerably worse on an empty stomach.

Step 4: When to raise it with your prescriber

There are situations where still eating on Mounjaro deserves a clinical conversation rather than patient reassurance. If you are several months into treatment, settled at a higher dose, and experiencing no appetite change and no measurable weight reduction, your prescriber needs to know. The NICE appraisal of tirzepatide (TA1026) notes that continuing treatment is reviewed if less than 5% weight loss has occurred after six months at the highest tolerated dose.

Other things worth flagging: eating compulsively or feeling that the medicine has triggered anxiety around food. These are not common, but they are real, and a prescriber can adjust the approach. For people who find the opposite is true (that the appetite reduction has become uncomfortably intense) not eating enough on Mounjaro covers that scenario separately.

If you are thinking about starting treatment and want to understand the broader picture first, our Mounjaro overview covers how the medicine works, the UK licensing position and what the consultation process involves. Treatment pricing varies by dose and provider; context on Mounjaro pricing in the UK explains the background behind the cost changes that took effect in autumn 2025. And if you have already started your journey and simply have questions, our FAQs cover many of the things people ask us week to week, including what to expect in the early months.

When you are ready to speak to a prescriber directly, you can start your free consultation with the nume clinical team. A GPhC-registered prescriber, not software, reads every consultation the same day.